All In Biotech

Drug Trial Radar · NCT07357727

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

460

Planned (sponsor's estimate)

Start

May 27, 2026

Primary completion

May 17, 2028

Study completion Dec 27, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.

Conditions

  • Primary Myelofibrosis (PMF)
  • Post-polycythemia Vera Myelofibrosis (PPV-MF)
  • Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Interventions

  • PelabresibDrug

    Pelabresib monohydrate tablets

  • RuxolitinibDrug

    Ruxolitinib phosphate tablets

  • PlaceboDrug

    Matches pelabresib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Splenic Response (SVR35) by Central Radiology Reads at Week 24 in participants with baseline total symptom score (TSS) ≥ 25Time frame: Week 24
  2. Absolute change from baseline in total symptom score (TSS) at Week 24 in participants with baseline TSS ≥ 25Time frame: Baseline, Week 24
  3. Number of Participants with Splenic Response (SVR35) by Central Radiology Reads at Week 24 in participants with baseline TSS ≥ 15Time frame: Week 24
  4. Absolute change from baseline in total symptom score (TSS) at Week 24 in participants with baseline TSS ≥ 15Time frame: Baseline, Week 24

Locations

174 sites in 24 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Yale University School Of Medicine

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialist South Reg

    Fort Myers, Florida · Recruiting

  • The Anderson Family Cancer Institute

    Jupiter, Florida · Recruiting

  • Miami NS Ins Baptist Health S FL

    Miami, Florida · Recruiting

  • Orlando Health Clinical Trials

    Orlando, Florida · Recruiting

  • Florida Cancer Specialists-North

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists East

    Stuart, Florida · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago Hospital

    Chicago, Illinois · Recruiting

  • Franciscan Health Indianapolis

    Indianapolis, Indiana · Recruiting

  • American Oncology Partners PA Center for Cancer and Blood Disorders

    Bethesda, Maryland · Recruiting

  • Michigan Med University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Summit Medical Group Oncology

    Berkeley Heights, New Jersey · Recruiting

  • New York Oncology Hematology P C

    Albany, New York · Recruiting

  • Columbia University Medical Center New York Presbyterian

    New York, New York · Recruiting

  • Sanford Research USD Fargo

    Fargo, North Dakota · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Texas Oncology - Central South

    Austin, Texas · Recruiting

  • Texas Oncology PA Dallas Presbyterian Hospital

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • SCRI Texas Oncology Northeast Texas

    Tyler, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Fred Hutch Cancer Research

    Seattle, Washington · Recruiting

  • Hospital Italiano de Buenos Aires

    CABA, Argentina · Recruiting

  • FUNDALEU

    Capital Federal, Argentina · Recruiting

  • Hospital Privado de Cordoba

    Córdoba, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Hospital de Clinicas Jose de San Martin

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Novartis Investigative Site

    Adelaide, South Australia, Australia · Recruiting

  • Novartis Investigative Site

    Clayton, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Graz, Austria · Recruiting

  • Novartis Investigative Site

    Salzburg, Austria · Recruiting

  • Novartis Investigative Site

    Sankt Pölten, Austria · Recruiting

  • Novartis Investigative Site

    Vienna, Austria · Recruiting

  • Novartis Investigative Site

    Roeselare, Belgium · Recruiting

  • Novartis Investigative Site

    Woluwe-Saint-Lambert, Brussels Capital, Belgium · Recruiting

  • Novartis Investigative Site

    Goiânia, Goiás, Brazil · Recruiting

  • Novartis Investigative Site

    Curitiba, Paraná, Brazil · Recruiting

  • Grupo ELORA

    Florianópolis, Santa Catarina, Brazil · Recruiting

Showing 40 of 174 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.